You are here

FDA Issues Approvable Letters for Pregabalin for Three Indications

NEW YORK, September 2, 2004 -- In response to media inquiries, Pfizer said it has received approvable letters from the US Food & Drug Administration for three indications for Lyrica (pregabalin): neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy in the treatment of partial seizures in adults. Pfizer received a non-approvable letter for Lyrica for the treatment of generalized anxiety disorder.

Pfizer said it is continuing to work closely with the FDA during the ongoing regulatory review to resolve open issues on all indications and labeling.

In the European Union, Lyrica received marketing approval in July 2004 for the management of peripheral neuropathic pain and as an adjunctive therapy in the treatment of partial seizures.

Source: Pfizer

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications